Saffron Mood Meta-analysis: What the Evidence Says

Quick Answer

Saffron Mood Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Difficulties in accessing healthcare, their high costs, personal preferences, and the perceived safety of medicinal herbs have contributed to the increased usage of herbalism. [Hasheminasab Fatemeh Sadat (2026); evidence level 1]
• Given their popularity, it is crucial to have up-to-date risk and benefit assessments on these herbal products. [Hasheminasab Fatemeh Sadat (2026); evidence level 1]
• Depression is a leading cause of disability worldwide and is characterised by sustained low mood, anhedonia, anergia, and a range of associated cognitive and somatic symptoms . [Muacevic Alexander (2026); evidence level 4]
• This literature review summarises key randomised controlled trials (RCTs), meta-analyses, safety data, dosing patterns, and guideline positioning for saffron in depressive disorders, with emphasis on adult major depressive disorder (MDD) and related depressive symptomatology. [Muacevic Alexander (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For saffron mood meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Hasheminasab Fatemeh Sadat (2026). Adverse Events of Saffron ( Crocus sativus L.): Systematic Review of Current Evidence. DOI: 10.1002/hsr2.72212. PMCID: PMC13121846. PMID: 42057871. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13121846/
• Muacevic Alexander (2026). The Role of Saffron in the Treatment of Depression: A Literature Review. DOI: 10.7759/cureus.104594. PMCID: PMC13044667. PMID: 41939549. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13044667/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.